ANIK Q3 2020 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q3 2020 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$32M+6.7% YoY

Gross Profit

$17M54.7% margin

Operating Income

-$8M-25.0% margin

Net Income

-$6M-20.2% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+3.3%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$416M

Total Liabilities

$132M

Stockholders' Equity

$284M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$30M	+6.7%
Gross Profit	$17M	$24M	-27.0%
Operating Income	-$8M	$12M	-165.8%
Net Income	-$6M	$9M	-169.7%

Revenue Segments

Product

$32M50%

Joint Pain Management Therapies

$18M29%

Orthopedic Joint Preservation and Restoration Care

$12M18%

Manufactured Product, Other

$2M2%

Geographic Segments

UNITED STATES

$26M90%

Europe

$3M10%